Dynamic quotes: Off
|
Company Description (as filed with the SEC)
GTx, Inc., a Delaware corporation incorporated on September 24, 1997 and headquartered in Memphis, Tennessee, is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions. We are developing selective androgen receptor modulators, or SARMs, a new class of drugs with the potential to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). Our lead SARM product candidate, enobosarm (also known as Ostarine® or GTx-024), has to date been evaluated in eight completed clinical trials enrolling approximately 600 subjects, including in a Phase Ib and two Phase II efficacy studies. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-0.65 |
| Quarterly EPS Est: | -0.21 |
| PEG Ratio: | -.01 |
|
Mean Recommendation: View Summary / View All |
1.8 |
Data is provided by Zacks Investment Research

